NanoViricides, Inc. (NNVC.PK) To Restart Its Anti-Ebola Virus Drug Development Program
8/4/2014 11:54:18 AM
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) reports that it is restarting its drug development program to combat Ebola virus infections.
The recent Ebola outbreak in West Africa has been the deadliest so far, per the World Health Organization (WHO). Ebola virus causes a deadly disease, with 60% to 90% of infected people dying, depending upon the strain of the virus. Fortunately, it is transmitted only through close contact with an infected person’s body fluids, and not through aerosol or the water route, thus limiting its transmission.
Help employers find you! Check out all the jobs and post your resume.
comments powered by